A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

Start Date18 Apr 2017

Sponsor / Collaborator

Biogen, Inc.

[+1]

NCT01929746

/ CompletedPhase 1

A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers

The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of BIIB019 (Daclizumab High Yield Process; DAC HYP) administered as a single subcutaneous (SC) dose (75 mg or 150 mg) Japanese and Caucasian adult healthy volunteers. The secondary objective of this study in this study population is to assess the safety and tolerability of BIIB019 administered as a single SC dose (75 mg or 150 mg).

Start Date01 Oct 2013

Sponsor / Collaborator

Biogen, Inc.

[+1]

NCT01797965

/ TerminatedPhase 3

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).
Secondary objectives of this study in this study population are as follows:
To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and participant-reported impact of MS, following long-term treatment with DAC HYP To assess the long-term immunogenicity of DAC HYP administered by prefilled syringe (PFS) To assess the safety, tolerability, and efficacy of switching to DAC HYP in participants previously on long-term treatment with interferon β-1a (Avonex) in Study 205MS301(NCT01064401).

Start Date15 Feb 2013

Sponsor / Collaborator

Biogen, Inc.

[+1]

100 Clinical Results associated with Daclizumab

100 Translational Medicine associated with Daclizumab

100 Patents (Medical) associated with Daclizumab

865

Literatures (Medical) associated with Daclizumab

01 Apr 2026·INTERNATIONAL IMMUNOPHARMACOLOGY

Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis

Article

Author: Tong, Zequn ; Gong, Ting ; Xiang, Niu ; Ji, Chao ; Li, Weixing ; Cheng, Bo ; Zou, Ying ; Xu, Qiuyun ; Zhao, XiaoYan ; Zhou, Kunli ; Cai, Liangqi

BACKGROUND:

Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence; however, the underlying immune mechanisms remain poorly understood. Precision therapeutics have shown promise, yet significant unmet clinical needs remain. Single-cell expression quantitative trait loci (sc-eQTL) combined with genome-wide association studies (GWAS) and mendelian randomization (MR) can provide cell-type-specific causal evidence for immune mechanisms in complex diseases METHODS: We integrated sc-eQTL data from 14 immune cell types (OneK1K cohort, n = 982) with AD GWAS summary statistics from FinnGen (n = 31,245) and GWAS Catalog (n = 22,474). We performed two-sample MR using inverse variance weighting and Wald ratio methods, with MR-Egger, MR-PRESSO, and Steiger directionality tests ensuring robustness. Co-localization analysis confirmed shared causal variants, and functional enrichment analyses explored candidate gene mechanisms.

RESULTS:

We identified 14 immune cell-specific hub genes (CD52, CD4 NC, IL2RA, TNF, HLA-DQB2, and others) with strong co-localization evidence (PP·H4 > 0.7). Enrichment analysis revealed significant clustering in MHC class II protein complexes and (e.g., HLA-DR, HLA-DP, HLA-DQ) and partially in TNF and MHC-I classes like HLAC. Pathway analysis indicated significant enrichment in immune-related pathways, including asthma and inflammatory bowel disease. Additionally, 46 drugs targeting these genes were identified, with 13 causal genes overlapping with known druggable targets, such as alemtuzumab (CD52), daclizumab (IL2RA), and TNF inhibitors.

CONCLUSIONS:

Our study provides genetic evidence supporting a causal role for immune cell-specific genes in AD susceptibility. The 14 hub genes and associated druggable targets establish a foundation for precision immunotherapy development in AD.

01 Jan 2026·Experimental and Clinical Transplantation

No Association of Sex or Racial Factors With Outcomes in Adult Intestine-Only Transplant: A United Network for Organ Sharing Database Analysis.

Article

Author: Tupper, Connor J ; Li, Meng-Hao ; Koizumi, Naoru ; Cogua, Laura M ; Ortiz, Jorge ; Faddoul, Giovanni

OBJECTIVES:

Adult intestine-only transplant is an uncommon procedure for intestinal failure. We assessed demographic factors associated with recipient mortality and graft failure rates in adult intestine-only transplant recipients.

MATERIALS AND METHODS:

Data for cases of adult intestine-only transplants diagnosed for the period 2004-2024 were collected from the United Network for Organ Sharing database. Demographic characteristics of recipients, mortality, and graft survival were evaluated among racial groups.

RESULTS:

A total of 896 transplants were included. Most were White (75.2%) and were female (56.3%). There were no differences in graft failure or recipient mortality by race/ethnicity or sex. Race/ethnicity was not associated with graft survival for adult intestine-only transplant. Recipient mortality was greater with older recipients (hazard ratio = 1.022; P = .007). Basiliximab/daclizumab was associated with a higher mortality rate (hazard ratio = 1.001; P < .001). There were no racial disparities and no differences in regimens for induction immunosuppression or maintenance immunosuppression with regard to recipient mortality or graft failure.

CONCLUSIONS:

Recipient age and basiliximab/daclizumab may significantly influence adult intestine-only transplant recipient survival but not graft outcomes.

01 Dec 2025·BIOELECTROCHEMISTRY

Temperature-driven changes in biofilm formation and electrochemical performance of deep-sea inoculum in microbial fuel cells

Article

Author: Vasumathi, K ; Wu, Chi ; Das, Bhanupriya ; Tumboimbela, Jessica Renata Wijaya ; Tritanti, Jovanka Sheryn ; Wang, Chin-Tsan

Microbial fuel cells (MFCs) generate electricity by converting organic materials and utilizing electroactive bacteria, where anodic biofilms play a vital role in electron transfer and controlling internal resistance. The adaptation of deep-sea microbial communities to diverse environmental conditions, particularly the effects of temperature on biofilm formation and MFC efficiency in high-salinity environments, remains under-explored. This study aims to fill this gap by examining how different temperatures (4 °C (F35), 25 °C (R35), and 37 °C (I35)) affect anodic biofilm formation and MFC performance. The research employs deep-sea sediment inoculum from the South China Sea to enhance understanding of microbial adaptability and optimize performance in extreme conditions. Among the tested conditions, I35 demonstrated the highest current and power densities at 172.49 mA/m² and 20.09 mW/m², representing increases of approximately 129 % and 350 % compared to F35. R35 displayed moderate output. Microbial analysis revealed that I35 had the highest CFU count at 7.67 × 10⁷ CFU/mL, with Gram staining and colony morphology indicating greater diversity and a higher abundance of electroactive Gram-negative populations at elevated temperatures. Performance improved with increased temperature; however, the power gains were more significant than variations in microbial counts, underscoring the importance of microbial composition, biofilm conductivity, and electron transfer efficiency. Despite having viable bacteria, F35 showed low output due to a less electroactive community and considerable charge transfer resistance. These findings highlight the need to enhance microbial quality, not just quantity, to improve MFC performance in extreme conditions and support the future application of thermally adapted biofilms in high-salinity MFC systems.

News (Medical) associated with Daclizumab

13 May 2026

·allsci.com

Pfizer terminates Phase I trial of anti-CD25 ADC PF-08046032 in oncology

Pfizer’s Phase I program for PF-08046032, an anti-CD25 antibody-drug conjugate designed to deplete immunosuppressive regulatory T cells within the tumor microenvironment, has been terminated after enrolling only six participants, marking one of the earliest discontinuations in the company’s recent oncology pipeline. The NCT06870487 trial terminated before completing dose escalation, the termination reflecting a strategic business decision rather than safety or efficacy concerns, as per the clinicaltrial.gov listing. The open-label Phase I study enrolled adults with advanced or metastatic malignancies across two broad disease categories: lymphomas, including classical Hodgkin lymphoma, peripheral T-cell lymphoma, and diffuse large B-cell lymphoma, and solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and melanoma. Patients were required to have an ECOG performance status of 0 or 1, measurable disease per RECIST 1.1 or Lugano criteria, and the ability to provide tumor tissue for correlative analyses. Primary endpoints focused on safety characterization. Pfizer has been executing a substantial cost-reduction program since 2024, eliminating multiple early-stage assets as part of a broader effort to redirect capital toward later-stage and revenue-generating oncology programs, including assets acquired through the Seagen transaction. An unvalidated Phase I asset with no efficacy signal and an uncertain differentiation profile would be a plausible candidate for deprioritization under that framework. The clinical trial termination in 2026 leaves the anti-CD25 ADC concept without a clinical proof of concept from this program. Pfizer has not indicated whether the asset will be restarted, out-licensed, or permanently discontinued. The scientific rationale for targeting CD25 on intratumoral Tregs is well established in the preclinical literature. Tregs suppress anti-tumor immune responses through multiple mechanisms, including CTLA-4-mediated co-stimulation blockade, IL-10 and TGF-beta secretion, and IL-2 consumption. Their depletion in the tumor microenvironment has been shown to enhance anti-tumor immunity in animal models, and the combination with PD-1 blockade was designed to provide complementary immune activation. The clinical translation of this concept has proven difficult. Basiliximab and daclizumab, earlier anti-CD25 antibodies developed for transplant indications, demonstrated the on-target pharmacology of CD25 blockade but were not developed as ADCs. More recent ADC-based approaches have sought to use payload delivery to achieve tumor-selective cytotoxicity without systemic immunosuppression, but the therapeutic window remains narrow given the expression of CD25 on activated T cells in the periphery. Several programs targeting Tregs through different mechanisms remain in early clinical development across the industry, including approaches targeting FOXP3, CCR8, and TNFR2. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 1ADCImmunotherapy

08 Jan 2026

·www.biospace.com

Osel Enters Agreement with SWOG Cancer Research Network for First-Ever Pivotal Trial of a Microbiome-Based Therapy in Oncology

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added toxicity MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Osel Inc., a clinical-stage biopharma company pioneering live biotherapeutic products (LBPs), today announced a clinical trial agreement with SWOG Cancer Research Network for a pivotal Phase 3 clinical trial of its lead oncology candidate, MO-03, in combination with standard immuno-oncology (IO) regimens for advanced and metastatic renal cell carcinoma (mRCC). This marks the first-ever pivotal trial of a microbiome-based oral therapy in oncology. The BIOFRONT trial will build on promising results from two prior clinical studies led by Dr. Sumanta Kumar Pal, MD, FASCO at City of Hope. In those studies, prior formulations of the product were added to nivolumab and ipilimumab or to cabozantinib and nivolumab and showed statistically significant improvements in response rates and progression free survival, without added toxicity. 1,2 A recent dose-escalation study confirmed favorable safety across higher dose levels, with no increase in immune-related adverse events, leading to a new high-potency capsule formulation, MO-03, specific for oncology. “The study represents a major advance for patients with advanced RCC,” said Dr. Pal. “While other combination approaches in the front-line setting add significant toxicity, MO-03 could possibly augment the efficacy of immunotherapy-based regimens without compromising quality of life.” The Phase 3 randomized, double-blind study will enroll approximately 700 patients across up to 150 SWOG sites in the United States, comparing MO-03 plus approved IO therapy versus placebo plus IO. The trial is supported by the National Cancer Institute (NCI), part of the National Institutes of Health. Trial initiation is slated for Q1 2026. MO-03 is a high-potency capsule formulation of Clostridium butyricum Miyairi 588 (CBM588), developed specifically for oncology by Osel and Japan’s Miyarisan Pharmaceutical Co., which will supply the GMP product. Osel holds the Investigational New Drug applications (INDs) for CBM588 and MO-03 in the United States and has exclusive marketing rights to CBM588 and MO-03 pharmaceutical products in the United States, Canada, and Europe. “We appreciate the investment that SWOG/NCI is making in this pivotal trial, which will position MO-03 as a first-in-class LBP in oncology,” said Peter P. Lee, MD, Chairman of Osel. “We are actively working with Miyarisan to engage partners who are interested in commercializing MO-03, pending positive Phase 3 results. Recent market research among US oncologists and payers shows strong interest in MO-03 and a high likelihood of coverage in the mRCC setting.” The BIOFRONT trial, formally titled “S2419, Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma,” is led by Principal Investigator (PI) Pedro C. Barata, MD, MSc, at University Hospitals Seidman Cancer Center. Co-PIs are Ulka Vaishampayan, MD, at University of Michigan Rogel Cancer Center, and Sumanta K. Pal, MD, at City of Hope. Osel holds the exclusive worldwide intellectual property rights for the use of Clostridium butyricum in oncology in combination with immune checkpoint inhibitors (ICIs) including the PD-1, PD-L1 and CTLA-4 inhibitors nivolumab, ipilimumab, pembrolizumab, cemiplimab, durvalumab, daclizumab, avelumab, or atezolizumab. The allowed claims specifically cover Clostridium butyricum as the sole live biotherapeutic product in combination regimens with ICIs and other anti-cancer agents. The intellectual property includes not only renal cell cancer but also extends to other major malignancies and microsatellite-instability high (MSI-H) cancers, including non-small cell lung cancer, melanoma, sarcoma, lymphoma, breast cancer, bladder cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, stomach cancer, or rectal cancer, supporting the broad clinical potential of MO-03. About Osel Inc. Osel Inc., a privately held biopharmaceutical company based in Mountain View, California, is focused on the development and commercialization of a portfolio of live biotherapeutic products (LBPs) to prevent or treat major medical conditions via modulation of the human microbiome. The company is a pioneer in the field of LBPs and primarily focuses on oncology and women’s health indications. Visit oselinc.com to learn more. References: 1. Ebrahimi H, Pal SK, et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024;30(9):2576 2585. doi: 10.1038/s41591-024-03086-4. 2. Dizman N, Pal SK, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704 712. doi: 10.1038/s41591-022-01694-6. Contacts Media Contact Colin Sanford colin@bioscribe.com Thomas Parks, PhD tparks@oselinc.com

Phase 3Phase 1ImmunotherapyClinical Result

07 Mar 2024

·www.biospace.com

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics. "He's been here before. His early-stage clinical experience in cystic fibrosis and non-cystic fibrosis bronchiectasis patient populations is a perfect match for our drug candidates that we believe will reshape the respiratory infectious disease landscape." "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics. "The high unmet medical need in this therapeutic area is significant. I am excited to advance our nebulized therapy to maximize clinical outcomes for these patients without concerns of renal toxicity and emergence of antibiotic resistance." Vast plans to initiate its Phase 1 clinical development program in Q2 2024 and one or more proof-of-concept studies in subjects with bronchiectasis in 2025. Paul Bruinenberg, MD, MBA – Chief Medical Officer Dr. Bruinenberg has over 30 years' experience in the pharmaceutical and biotechnology industry. He brings a wealth of respiratory infectious disease experience researching rare diseases like cystic fibrosis (CF), non-CF bronchiectasis (NCFB), tuberculosis (TB) and non-tuberculosis mycobacteria (NTM). His career includes development of several inhaled therapies including the approval of Pulmozyme® as the first mucolytic for CF as well as the early development of inhaled liposomal ciprofloxacin for the treatment of chronic Pseudomonas aeruginosa infections. Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections. Previously, he held medical leadership roles at Eagle Pharmaceuticals, Aradigm Corporation, Astellas and Roche, having a key role in the development and approval of 12 new drugs (Pulmozyme®, Pretonamid®, Globocef®, Rocephin®, Quinodis® Bosentan®, Xolair®, CellCept®, Zenapax®, Belrapzo®, Bendeka®, and Ryanodex®). Dr. Bruinenberg is a graduate of the medical school of the University of the Stellenbosch, South Africa and obtained two MBAs from the University of Nijenrode in the Netherlands and Rochester University in the USA. Chris Polage, MD – Medical Director Dr. Polage is a physician-scientist and board-certified medical microbiologist with NIH clinical research training and over 15 years of experience leading top academic clinical laboratories. His award-winning research and publications have been cited more than 2500 times in the medical and scientific literature and changed medical practice regarding the diagnosis and treatment of C. difficile, an urgent antimicrobial resistance threat. Before coming to Vast, he was Medical Director of the Duke University Clinical Microbiology Laboratory where he oversaw specialized testing for a broad array of patient populations including CF and NCFB patients. Dr. Polage is a diagnostics expert for the NIAID/NIH Antimicrobial Resistance Leadership Group and an adjunct Associate Professor of Pathology at Duke University. He received his Doctor of Medicine from the University of New Mexico with residency and fellowship training at the University of Colorado and University of Utah/ARUP Laboratories, including two years of medical microbiology with a special focus on mycobacterial testing. About Vast Therapeutics Vast is a life science company focused on breaking the debilitating cycle of infection and chronic inflammation in respiratory diseases. This cycle affects patients across the entire spectrum of human life, ranging from children with rare orphan diseases like Cystic Fibrosis to adults with highly prevalent diseases like chronic obstructive pulmonary disease (COPD). We believe our product candidates may provide an effective treatment for patients infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes. Contact: Nathan Stasko Chief Executive Officer Vast Therapeutics, Inc. nstasko@vasttherapeutics.com

Executive ChangeMicrobial therapy

100 Deals associated with Daclizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D03639	Daclizumab	L04AC01	DB00111

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Canada	Biogen, Inc.	08 Dec 2016
Multiple Sclerosis	United States	Biogen, Inc.	27 May 2016
Renal transplant rejection	European Union	Roche Registration Ltd.	26 Feb 1999
Renal transplant rejection	Iceland	Roche Registration Ltd.	26 Feb 1999
Renal transplant rejection	Liechtenstein	Roche Registration Ltd.	26 Feb 1999
Renal transplant rejection	Norway	Roche Registration Ltd.	26 Feb 1999
Graft Rejection	United States	F. Hoffmann-La Roche Ltd.	10 Dec 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allograft Rejection	Phase 2	United States	Roche Pharma AG	01 Oct 2003
Colitis, Ulcerative	Phase 2	United States	Abbott Biotherapeutics Corp.	01 Apr 2003
Colitis, Ulcerative	Phase 2	Belgium	Abbott Biotherapeutics Corp.	01 Apr 2003
Colitis, Ulcerative	Phase 2	Canada	Abbott Biotherapeutics Corp.	01 Apr 2003
Persistent asthma	Phase 2	United States	Abbott Biotherapeutics Corp.	01 Sep 2001
Diabetes Mellitus, Type 1	Phase 2	United States	Abbott Biotherapeutics Corp.	01 Jul 2000
Diabetes Mellitus, Type 1	Phase 2	United States	Roche Pharma AG	01 Jul 2000
Psoriasis vulgaris	Phase 2	United States	Abbott Biotherapeutics Corp.	01 Oct 1997

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	-	17	Daclizumab	tbgqnfgutm(ocznrlcich) = ojxymfhchj gihguqcswj (imzntrqrha ) View more	Positive	06 Dec 2025
ASH2024 Manual	Not Applicable	Thalassemia	169	Daclizumab + standard GvHD prophylaxis	sbvwxjdrur(qwzckjbpra) = nqtckrebzm aocpcjzjno (ksgvjfacpj ) View more	Positive	07 Dec 2024
ASH2024 Manual	Not Applicable	Thalassemia	169	Standard GvHD prophylaxis	sbvwxjdrur(qwzckjbpra) = qxdokuhkzj aocpcjzjno (ksgvjfacpj ) View more	Positive	07 Dec 2024
NCT00246129 (CTgov)	Phase 4	Renal Insufficiency	123	Campath (Campath-Tacrolimus)	mhhyokhqnt = jhgpuxovgh msmsbsradt (smqjarrolq, pqusghsajs - jeqhdnelpj) View more	-	29 Sep 2021
NCT00246129 (CTgov)	Phase 4	Renal Insufficiency	123	Daclizumab (Daclizumab-Tacrolimus-Mycophenolate)	mhhyokhqnt = bbamzkzobm msmsbsradt (smqjarrolq, whrnfyjkvb - vlfmmqxedz) View more	-	29 Sep 2021
NCT01797965 (EXTEND, Pubmed \| Ther Adv Neurol Disord) Manual	Phase 3	Multiple sclerosis relapse	1,203	daclizumab beta	tbhtmqekqa(qvhpjqijiz) = djmoayridg tpesghalns (xlxtueiddy ) View more	Negative	26 Feb 2021
NCT01051349 (SELECTED, Pubmed \| J Neurol) Manual	Phase 2	Multiple Sclerosis, Relapsing-Remitting	455	Daclizumab	vwwiiuwjkw(ucedttpwxx) = avfgpiupxq ltqgpppleb (zawdmtxuby ) View more	Positive	01 Oct 2020
NCT01797965 (EXTEND, CTgov)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	1,501	IFN β-1a+DAC HYP (IFN β-1a 30 µg (301)/DAC HYP 150 mg (303))	nfkrubuuse = itpghrnnhc jbiracxhnb (jntaqfdesw, qjugzqxtfy - xsznxmvprx) View more	-	04 Dec 2019
NCT01797965 (EXTEND, CTgov)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	1,501	DAC HYP (DAC HYP 150 mg (301) /DAC HYP 150 mg (303))	nfkrubuuse = xfmlcffifw jbiracxhnb (jntaqfdesw, iedbxtcufq - ejdjzziotc) View more	-	04 Dec 2019
NCT02881567 (SUSTAIN, CTgov)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	41	Daclizumab	qrcmsjkimz = xjxqawejwc tzqbuyffml (avhtmcfgrh, pqvsprkhbh - kpnjnpljox) View more	-	24 Sep 2019
EAN2019	Not Applicable	Multiple Sclerosis	-	Daclizumab	oirrucusan(mssrtdawff) = no relevant complication â liver impairment and encephalitis included - was observed mtfnxdnxgi (ajscegpfnw )	-	27 Jun 2019
NCT01064401 (DECIDE, Pubmed \| Mult Scler) Manual	Phase 3	Multiple Sclerosis	24	daclizumab beta	qeqjldqnba(tsgqhtddjn): HR = 0.73 (95% CI, 0.55 - 0.98) View more	Similar	01 Dec 2018
NCT01064401 (DECIDE, Pubmed \| Mult Scler) Manual	Phase 3	Multiple Sclerosis	24	interferon beta-1a		Similar	01 Dec 2018
NCT01051349 (SELECTED, CTgov)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	410	trivalent seasonal influenza vaccine+BIIB019 (Daclizumab)	iygyjtnlfg = pilaatmgrc vrqrmhvdfw (bcswuqqdqg, ujibmlzxux - xsdilzpcea) View more	-	09 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis